# PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis

> **NCT07256197** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Beijing Anzhen Hospital** · enrollment: 160 (estimated)

## Conditions studied

- Aortic Stenosis, Calcific

## Interventions

- **DRUG:** Treatment with PCSK9 inhibitors
- **OTHER:** Treatment without PCSK9 inhibitors

## Key facts

- **NCT ID:** NCT07256197
- **Lead sponsor:** Beijing Anzhen Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- Beijing Jishuitan Hospital
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Beijing Hospital
- Nanchong Central Hospital
- Peking University First Hospital
- Beijing Luhe Hospital

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07256197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07256197, "PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07256197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*